Corcept's Relacorilant Rejected, Stock Plummets
Update: 2026-01-05
Description
Corcept Therapeutics Stock Tumbles After FDA Rejects New Drug Application: The biopharma companys plans to expand beyond its successful Korlym treatment are on hold following the FDAs rejection of its new drug application for relacorilant, a treatment for high blood pressure linked to excess cortisol levels. The news has shaken investor confidence, with the companys stock trading at a significant discount to its fifty-two-week high. Checkout Solipillow.com
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
